RNTX
HEALTHCARERein Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving RNTX Today?
No stock-specific AI insight has been generated for RNTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.17
Fundamentals
Trading
RNTX News
17 articles- Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common StockYahoo Finance·May 1, 2026
- Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary FibrosisYahoo Finance·Apr 29, 2026
- Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary FibrosisYahoo Finance·Mar 3, 2026
- Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary FibrosisYahoo Finance·Jan 20, 2026
- Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPFYahoo Finance·Nov 6, 2025
- Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisYahoo Finance·Nov 3, 2025
- Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisYahoo Finance·Oct 9, 2025
- Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary FibrosisYahoo Finance·Sep 17, 2025
- Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst callsYahoo Finance·Aug 19, 2025
- Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary FibrosisYahoo Finance·Aug 19, 2025
- Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025Yahoo Finance·Aug 14, 2025
- Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingYahoo Finance·Jul 30, 2025
- Rein Therapeutics Announces Adjournment of Annual Meeting of StockholdersYahoo Finance·Jun 24, 2025
- Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFYahoo Finance·May 27, 2025
- Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International ConferenceYahoo Finance·May 19, 2025
- Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·May 15, 2025
- Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFYahoo Finance·May 12, 2025
All 17 articles loaded
Price Data
52-Week Range
$1.17
Fundamentals
Trading
About Rein Therapeutics Inc
Rein Therapeutics Inc (RNTX) is a forward-thinking biopharmaceutical firm dedicated to pioneering next-generation therapies for neurodegenerative disorders. By harnessing its proprietary technology platform that fuses advanced neuroscience with innovative drug development, the company is well-positioned to tackle significant unmet medical needs through a robust pipeline of candidates. With a leadership team composed of industry veterans, Rein Therapeutics operates within a dynamic therapeutic landscape, making it an attractive opportunity for institutional investors focused on breakthrough healthcare advancements.